Wednesday, July 8, 2026

biotech · Blepharitis · Meibomian Gland Dysfunction · TARS

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is a biotech organization headquartered in Irvine, USA. It trades on NYSE under ticker TARS. Primary therapeutic focus areas include Blepharitis, Meibomian Gland Dysfunction, Papulopustular Rosacea

15440 Laguna Canyon Rd, Irvine, California 92618, US HQ
2017 Founded
403 Employees
Public company Type
TARS · NYSE Ticker
Company details
Status
Public
HQ
15440 Laguna Canyon Rd, Irvine, California 92618, US
Founded
2017
Employees
403
Programs
14
Drugs
10
Patents
9
Clinical program

Uteratonic administration

Unknown · small molecule · Placenta Abruptio

Uteratonic administration for Placenta Abruptio is a Unknown program (small_molecule) at Tarsus Pharmaceuticals with 1 ClinicalTrials.gov record(s).

← All Tarsus Pharmaceuticals projects Unknown small molecule active

Internal code Sengul Ulucam

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Tarsus Pharmaceuticals
Phase
Unknown
Modality
small_molecule
Indication
Placenta Abruptio
Status
active
Trials
1

Clinical trials